Latest News

Ultrasound offers advantages for long-term lymph node surveillance in high-grade SCC patients


 

EXPERT ANALYSIS FROM the ACMS Annual Meeting

– Ultrasound can be a very effective way to track early nodal metastasis in patients with high-stage cutaneous squamous cell carcinomas, and at a fraction of the cost of other imaging modalities.

ultrasound machine Bogdanhoda/Thinkstock

The technique shows not only abnormal variations in the shape of nodes, but changes in the core and outer density, and vascular patterns, Emily Ruiz, MD, said at the annual meeting of the American College of Mohs Surgery. And over a 2-year surveillance period, this costs thousands less than radiation-based imaging.

Dr. Ruiz, director of the High-Risk Skin Cancer Clinic at Dana-Farber/Brigham and Women’s Cancer Center, Boston, said the standard imaging technique at that center used to be serial CT scans performed at diagnosis and every 6 months thereafter, for 2 years. But recently, the protocol changed: Ultrasound is now the preferred technique.

“The big problem with CT in this earlier disease, is that it can only identify the nodes that are enlarged, and doesn’t tell us anything about the etiology. Ultrasound, on the other hand, looks at a number of different features of the node.”

Tracking high-risk squamous cell carcinoma patients is a must, she said. “About 4% of people diagnosed with high-risk SCC will develop nodal metastases, and 1.5% of those will die from disease-specific death,” most often from locoregional disease. “So it’s critical to identify nodal diseases early as possible. Earlier identification leads to better outcomes.” Ultrasound simply provides more information about nodal metastasis, Dr. Ruiz added.

Pages

Recommended Reading

Skin signs may be good omens during cancer therapy
MDedge Hematology and Oncology
FDA approves cemiplimab for advanced cutaneous squamous cell carcinoma
MDedge Hematology and Oncology
Long-term mogamulizumab appears safe, effective in CTCL
MDedge Hematology and Oncology
IPH4102 on fast track for Sézary syndrome
MDedge Hematology and Oncology
Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
MDedge Hematology and Oncology
Increased risk of second cancers in mycosis fungoides
MDedge Hematology and Oncology
BCL expression intensity key in distinguishing FL lesions
MDedge Hematology and Oncology
Pembrolizumab extends Merkel cell PFS, OS
MDedge Hematology and Oncology
CLL, GVHD may raise risk for skin cancer after allo-HCT
MDedge Hematology and Oncology
Dr. Douglas Paauw gives updates on antihypertensives, statins, SGLT2 inhibitors
MDedge Hematology and Oncology